サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1392257

微生物APIの世界市場：産業分析、規模、シェア、成長、動向、予測（2023～2030年）

Global Microbial API Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日: | 発行: Value Market Research | ページ情報: 英文 335 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
微生物APIの世界市場：産業分析、規模、シェア、成長、動向、予測（2023～2030年）
出版日: 2023年11月01日
発行: Value Market Research
ページ情報: 英文 335 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の微生物APIの市場規模は、2022年に602億1,000万米ドルとなり、2023～2030年の予測期間中にCAGR 7.21%で成長し、2030年には約1,050億9,000万米ドルに達すると予測されています。

微生物APIとは、細菌、真菌、その他の微生物に由来する医薬品原薬を指します。これらのAPIは、体内で薬理効果を発揮する医薬品の中心的な治療成分です。

市場力学：

微生物API市場の成長は、相互に関連する複数の要因によって牽引されています。感染症や抗生物質耐性の増加による抗生物質需要の高まりが、微生物APIの必要性を後押ししています。特にバイオテクノロジーと遺伝子工学における技術の進歩は、微生物発酵に革命をもたらし、複雑なAPIを生産する上でより効率的でコスト効率の高いものとなっています。製薬業界の拡大と革新的医薬品の追求は、特にバイオ医薬品への注目が高まる中、多様な微生物由来原薬の需要に大きく寄与しています。新薬開発を促進するイニシアチブとともに、医薬品の安全性と有効性をサポートする政府の規制は、この市場にプラスの影響を与えています。製薬企業と研究機関の共同研究は、研究開発への多額の投資と相まって、微生物APIの発見と生産を加速させています。ヘルスケアへの支出と意識の高まりに後押しされた新興国での市場の拡大は、手頃な価格の医薬品への需要をさらに促進しています。さらに、微生物による原薬製造法は環境面で持続可能であることから、従来の化学合成法よりも好まれる傾向にあり、微生物を利用した医薬品製造の有望な未来を育んでいます。

調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは微生物APIの世界市場における各セグメントを包括的に評価することもできます。微生物API産業の成長と動向は、この調査に全体的なアプローチを提供します。

地域分析：

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける微生物API市場の現在と将来の需要を強調する地域展望をカバーしています。さらに、本レポートは、すべての主要地域における個々のアプリケーションセグメントの需要、推定・予測に焦点を当てています。

ご要望がございましたら、弊社までご連絡ください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 微生物API - 業界分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場魅力度分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 微生物APIの世界市場分析：宿主別

  • 宿主別概要
  • 実績データと予測データ
  • 宿主別分析
  • 哺乳類
  • 細菌
  • 真菌

第6章 微生物APIの世界市場分析：タイプ別

  • タイプ別概要
  • 実績データと予測データ
  • タイプ別分析
  • 抗体
  • ペプチド
  • タンパク質
  • 低分子
  • ワクチン

第7章 微生物APIの世界市場分析：サイト別

  • サイト別概要
  • 実績データと予測データ
  • サイト別分析
  • インハウス
  • アウトソーシング

第8章 微生物APIの世界市場分析：最終用途別

  • 最終用途別概要
  • 実績データと予測データ
  • 最終用途別分析
  • 製薬企業
  • バイオ医薬品企業
  • その他

第9章 微生物APIの世界市場分析：分子別

  • 分子別概要
  • 実績データと予測データ
  • 分子別分析
  • 革新的
  • ジェネリック

第10章 微生物APIの世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他の欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他のアジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他のラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他の中東・アフリカ

第11章 微生物API企業の競合情勢

  • 微生物API市場の競合
  • パートナーシップ／提携／協定
  • 合併・買収
  • 新製品発売
  • その他の開発

第12章 企業プロファイル

  • 企業シェア分析
  • 市場集中度
  • Merck & Co. Inc.
  • Topfond Pharmaceutical Co. Ltd.
  • DSM
  • CSPC Pharmaceutical Group Limited
  • KOLON LIFE SCIENCE
  • Shandong Lukang Pharmaceutical Co. Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Lonza
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis by Host (USD MN)
  • Mammalian Market Sales by Geography (USD MN)
  • Bacterial Market Sales by Geography (USD MN)
  • Fungal Market Sales by Geography (USD MN)
  • Analysis Market by Type (USD MN)
  • Antibody Market Sales by Geography (USD MN)
  • Peptide Market Sales by Geography (USD MN)
  • Protein Market Sales by Geography (USD MN)
  • Small Molecule Market Sales by Geography (USD MN)
  • Vaccine Market Sales by Geography (USD MN)
  • Analysis by Site (USD MN)
  • In-house Market Sales by Geography (USD MN)
  • Outsourced Market Sales by Geography (USD MN)
  • Analysis by End-use (USD MN)
  • Pharmaceutical Companies Market Sales by Geography (USD MN)
  • Biopharmaceutical Companies Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis by Molecule (USD MN)
  • Innovative Market Sales by Geography (USD MN)
  • Generic Market Sales by Geography (USD MN)
  • Global Microbial Api Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Microbial Api Report
  • Market Research Process
  • Market Research Methodology
  • Global Microbial Api Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Host
  • Market Attractiveness Analysis by Type
  • Market Attractiveness Analysis by Site
  • Market Attractiveness Analysis by End-use
  • Market Attractiveness Analysis by Molecule
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Host (USD MN)
  • Mammalian Market Sales by Geography (USD MN)
  • Bacterial Market Sales by Geography (USD MN)
  • Fungal Market Sales by Geography (USD MN)
  • Global Market Analysis by Type (USD MN)
  • Antibody Market Sales by Geography (USD MN)
  • Peptide Market Sales by Geography (USD MN)
  • Protein Market Sales by Geography (USD MN)
  • Small Molecule Market Sales by Geography (USD MN)
  • Vaccine Market Sales by Geography (USD MN)
  • Global Market Analysis by Site (USD MN)
  • In-house Market Sales by Geography (USD MN)
  • Outsourced Market Sales by Geography (USD MN)
  • Global Market Analysis by End-use (USD MN)
  • Pharmaceutical Companies Market Sales by Geography (USD MN)
  • Biopharmaceutical Companies Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Molecule (USD MN)
  • Innovative Market Sales by Geography (USD MN)
  • Generic Market Sales by Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR112112866

The global demand for Microbial API Market is presumed to reach the market size of nearly USD 105.09 BN by 2030 from USD 60.21 BN in 2022 with a CAGR of 7.21% under the study period 2023 - 2030.

Microbial API refers to Active Pharmaceutical Ingredients derived from microorganisms, such as bacteria, fungi, or other microorganisms. These APIs are the core therapeutic components in medications that exert a pharmacological effect on the body.

MARKET DYNAMICS:

The microbial API market's growth is driven by multiple interconnected factors. Heightened demand for antibiotics due to increasing infections and antibiotic resistance propels the need for microbial-derived APIs. Technological advancements, particularly in biotechnology and genetic engineering, have revolutionized microbial fermentation, making it more efficient and cost-effective for producing complex APIs. The pharmaceutical industry's expansion and pursuit of innovative drugs contribute significantly to the demand for diverse microbial APIs, especially as the focus on biopharmaceuticals intensifies. Government regulations supporting drug safety and efficacy, alongside initiatives promoting new drug development, positively influence this market. Collaborations between pharmaceutical firms and research institutions, coupled with substantial investments in R&D, accelerate microbial API discovery and production. The market's expansion in emerging economies, driven by increased healthcare spending and awareness, further fuels the demand for affordable medications. Additionally, the environmental sustainability of microbial API production methods has led to their preference over traditional chemical synthesis, fostering a promising future for microorganism-based pharmaceutical manufacturing.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of microbial api. The growth and trends of microbial api industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the microbial api market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Host

  • Mammalian
  • Bacterial
  • Fungal

By Type

  • Antibody
  • Peptide
  • Protein
  • Small Molecule
  • Vaccine

By Site

  • In-House
  • Outsourced

By End-Use

  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Others

By Molecule

  • Innovative
  • Generic

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Microbial API market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Microbial API market include Merck & Co., Inc., Topfond Pharmaceutical Co., Ltd., DSM, CSPC Pharmaceutical Group Limited, KOLON LIFE SCIENCE, Shandong Lukang Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., Lonza. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . MICROBIAL API - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Host
    • 3.7.2 Market Attractiveness Analysis By Type
    • 3.7.3 Market Attractiveness Analysis By Site
    • 3.7.4 Market Attractiveness Analysis By End-use
    • 3.7.5 Market Attractiveness Analysis By Molecule
    • 3.7.6 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL MICROBIAL API MARKET ANALYSIS BY HOST

  • 5.1 Overview by Host
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Host
  • 5.4 Mammalian Historic and Forecast Sales by Regions
  • 5.5 Bacterial Historic and Forecast Sales by Regions
  • 5.6 Fungal Historic and Forecast Sales by Regions

6 . GLOBAL MICROBIAL API MARKET ANALYSIS BY TYPE

  • 6.1 Overview by Type
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Type
  • 6.4 Antibody Historic and Forecast Sales by Regions
  • 6.5 Peptide Historic and Forecast Sales by Regions
  • 6.6 Protein Historic and Forecast Sales by Regions
  • 6.7 Small Molecule Historic and Forecast Sales by Regions
  • 6.8 Vaccine Historic and Forecast Sales by Regions

7 . GLOBAL MICROBIAL API MARKET ANALYSIS BY SITE

  • 7.1 Overview by Site
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Site
  • 7.4 In-house Historic and Forecast Sales by Regions
  • 7.5 Outsourced Historic and Forecast Sales by Regions

8 . GLOBAL MICROBIAL API MARKET ANALYSIS BY END-USE

  • 8.1 Overview by End-use
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by End-use
  • 8.4 Pharmaceutical Companies Historic and Forecast Sales by Regions
  • 8.5 Biopharmaceutical Companies Historic and Forecast Sales by Regions
  • 8.6 Others Historic and Forecast Sales by Regions

9 . GLOBAL MICROBIAL API MARKET ANALYSIS BY MOLECULE

  • 9.1 Overview by Molecule
  • 9.2 Historical and Forecast Data
  • 9.3 Analysis by Molecule
  • 9.4 Innovative Historic and Forecast Sales by Regions
  • 9.5 Generic Historic and Forecast Sales by Regions

10 . GLOBAL MICROBIAL API MARKET ANALYSIS BY GEOGRAPHY

  • 10.1. Regional Outlook
  • 10.2. Introduction
  • 10.3. North America Sales Analysis
    • 10.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.3.2. North America By Segment Sales Analysis
    • 10.3.3. North America By Country Sales Analysis
    • 10.3.4. United State Sales Analysis
    • 10.3.5. Canada Sales Analysis
    • 10.3.6. Mexico Sales Analysis
  • 10.4. Europe Sales Analysis
    • 10.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.4.2. Europe by Segment Sales Analysis
    • 10.4.3. Europe by Country Sales Analysis
    • 10.4.4. United Kingdom Sales Analysis
    • 10.4.5. France Sales Analysis
    • 10.4.6. Germany Sales Analysis
    • 10.4.7. Italy Sales Analysis
    • 10.4.8. Russia Sales Analysis
    • 10.4.9. Rest Of Europe Sales Analysis
  • 10.5. Asia Pacific Sales Analysis
    • 10.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.5.2. Asia Pacific by Segment Sales Analysis
    • 10.5.3. Asia Pacific by Country Sales Analysis
    • 10.5.4. China Sales Analysis
    • 10.5.5. India Sales Analysis
    • 10.5.6. Japan Sales Analysis
    • 10.5.7. South Korea Sales Analysis
    • 10.5.8. Australia Sales Analysis
    • 10.5.9. South East Asia Sales Analysis
    • 10.5.10. Rest Of Asia Pacific Sales Analysis
  • 10.6. Latin America Sales Analysis
    • 10.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.6.2. Latin America by Segment Sales Analysis
    • 10.6.3. Latin America by Country Sales Analysis
    • 10.6.4. Brazil Sales Analysis
    • 10.6.5. Argentina Sales Analysis
    • 10.6.6. Peru Sales Analysis
    • 10.6.7. Chile Sales Analysis
    • 10.6.8. Rest of Latin America Sales Analysis
  • 10.7. Middle East & Africa Sales Analysis
    • 10.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 10.7.2. Middle East & Africa by Segment Sales Analysis
    • 10.7.3. Middle East & Africa by Country Sales Analysis
    • 10.7.4. Saudi Arabia Sales Analysis
    • 10.7.5. UAE Sales Analysis
    • 10.7.6. Israel Sales Analysis
    • 10.7.7. South Africa Sales Analysis
    • 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE MICROBIAL API COMPANIES

  • 11.1. Microbial Api Market Competition
  • 11.2. Partnership/Collaboration/Agreement
  • 11.3. Merger And Acquisitions
  • 11.4. New Product Launch
  • 11.5. Other Developments

12 . COMPANY PROFILES OF MICROBIAL API INDUSTRY

  • 12.1. Company Share Analysis
  • 12.2. Market Concentration Rate
  • 12.3. Merck & Co. Inc.
    • 12.3.1. Company Overview
    • 12.3.2. Company Revenue
    • 12.3.3. Products
    • 12.3.4. Recent Developments
  • 12.4. Topfond Pharmaceutical Co. Ltd.
    • 12.4.1. Company Overview
    • 12.4.2. Company Revenue
    • 12.4.3. Products
    • 12.4.4. Recent Developments
  • 12.5. DSM
    • 12.5.1. Company Overview
    • 12.5.2. Company Revenue
    • 12.5.3. Products
    • 12.5.4. Recent Developments
  • 12.6. CSPC Pharmaceutical Group Limited
    • 12.6.1. Company Overview
    • 12.6.2. Company Revenue
    • 12.6.3. Products
    • 12.6.4. Recent Developments
  • 12.7. KOLON LIFE SCIENCE
    • 12.7.1. Company Overview
    • 12.7.2. Company Revenue
    • 12.7.3. Products
    • 12.7.4. Recent Developments
  • 12.8. Shandong Lukang Pharmaceutical Co. Ltd.
    • 12.8.1. Company Overview
    • 12.8.2. Company Revenue
    • 12.8.3. Products
    • 12.8.4. Recent Developments
  • 12.9. Teva Pharmaceutical Industries Ltd.
    • 12.9.1. Company Overview
    • 12.9.2. Company Revenue
    • 12.9.3. Products
    • 12.9.4. Recent Developments
  • 12.10. Lonza
    • 12.10.1. Company Overview
    • 12.10.2. Company Revenue
    • 12.10.3. Products
    • 12.10.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies